Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2022-07-29 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
CHAIR SUCCESSION
Foreign Filer Report
2022-07-29 English
Chair succession
Board/Management Information Classification · 99% confidence The document is a formal announcement disseminated via RNS (London Stock Exchange news service). The core content announces a change in senior leadership: Michel Demaré succeeding Leif Johansson as Non-Executive Chair of the Board. This directly relates to changes in the company's board of directors or senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document is short and serves as an announcement, not a detailed report, confirming it is not a 10-K, AR, or IR.
2022-07-29 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half (H1) of 2022, titled 'H1 2022 results'. It contains detailed financial statements, revenue and EPS summaries, management commentary on business performance, guidance updates, and pipeline highlights. It is not a mere announcement of a report (RPA) because it provides the actual substantive financial data and analysis. It fits the definition of an Interim/Quarterly Report (IR) as it covers a period shorter than a full fiscal year. H1 2022
2022-07-29 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half (H1) of 2022 for AstraZeneca PLC. It contains detailed financial statements, revenue breakdowns, EPS summaries, guidance updates, and management commentary on business performance. It is not an announcement of a report (RPA) because it provides the actual financial data and analysis. It is not a full Annual Report (10-K) as it covers only the interim period. Therefore, it is classified as an Interim / Quarterly Report. H1 2022
2022-07-29 English
TEZSPIRE RECOMMENDED FOR EU APPROVAL IN ASTHMA
Foreign Filer Report
2022-07-25 English
ULTOMIRIS RECOMMENDED FOR EU APPROVAL FOR GMG
Foreign Filer Report
2022-07-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.